Moderna's stock more than doubled on August 19, 2026 after the company announced positive initial results from a study of its experimental mRNA-based cancer vaccine developed with Merck, which is designed to be tailored to individual patients. The treatment is called intismeran.
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment.
this outlet adds: julesburgadvocate, 2026, course, merck, developing, based, vaccine
this outlet adds: apnews, article, mode, wouldn, great, dump, developed
this outlet adds: percent, vaccine, shows, early, success, melanoma, personalized, intismeran
this outlet adds: merck, developing, using, based, vaccine, called, intismeran, designed
this outlet adds: crossing, fingers, apnews, article, mode
Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test AP News